{
  "source": "PA-Notification-Inbrija.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1280-7\nProgram Prior Authorization/Notification\nMedication Inbrija® (levodopa inhalation powder)\nP&T Approval Date 5/2019, 5/2020, 5/2021, 5/2022, 5/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nInbrija® (levodopa inhalation powder) is an aromatic amino acid indicated for the intermittent\ntreatment of OFF episodes in patients with Parkinson’s disease treated with\ncarbidopa/levodopa.\nInbrija should only be administered with the Inbrija inhaler.\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Inbrija will be approved based on all of the following criteria:\na. Diagnosis of Parkinson’s disease\n- AND-\nb. Used as intermittent treatment for OFF episodes\n- AND-\nc. Patient is currently on and will continue to receive treatment with a\ncarbidopa/levodopa-containing medication\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Inbrija will be approved based on the following criteria:\na. Documentation of positive clinical response to Inbrija therapy\n- AND-\nb. Patient will continue to receive treatment with a carbidopa/levodopa-containing\nmedication\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Inbrija [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; December 2022.\nProgram",
    "ies by\nprogram and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Inbrija [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; December 2022.\nProgram Prior Authorization/Notification - Inbrija® (levodopa inhalation\npowder)\nChange Control\n5/2019 New program\n5/2020 Annual review. Updated reference.\n5/2021 Annual review. Updated reference.\n5/2022 Annual review with no change to clinical criteria.\n5/2023 Annual review with no change to clinical criteria. Added state mandate\nfootnote. Updated reference.\n2/2024 Revised initial authorization to 12 months.\n2/2025 Annual review with no change to clinical criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}